Jianhua Yin, Yingze Zhao, Fubaoqian Huang, Yunkai Yang, Yaling Huang, Zhenkun Zhuang, Yanxia Wang, Zhifeng Wang, Xiumei Lin, Yuhui Zheng, Wenwen Zhou, Shuo Wang, Ziqian Xu, Beiwei Ye, Yaxin Guo, Wenwen Lei, Lei Li, Jinmin Tian, Jinxian Gan, Hui Wang, Wei Wang, Peiyao Ma, Chang Liu, Xiaoyu Wei, Xuyang Shi, Zifei Wang, Yang Wang, Ying Liu, Mingming Yang, Yue Yuan, Yumo Song, Wen Ma, Zhuoli Huang, Ya Liu, Yunting Huang, Haorong Lu, Peipei Liu, Hao Liang, Yong Hou, Xun Xu, Longqi Liu, Yuntao Zhang, Guizhen Wu, George F Gao, Xin Jin, Chuanyu Liu, Xiaoming Yang, William J Liu
The BBIBP-CorV severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inactivated vaccine has been authorized for emergency use and widely distributed. We used single-cell transcriptome sequencing to characterize the dynamics of immune responses to the BBIBP-CorV inactivated vaccine. In addition to the expected induction of humoral immunity, we found that the inactivated vaccine induced multiple, comprehensive immune responses, including significantly increased proportions of CD16+ monocytes and activation of monocyte antigen presentation pathways; T-cell activation pathway upregulation in CD8+ T cells, along with increased activation of CD4+ T cells; significant enhancement of cell-cell communications between innate and adaptive immunity; and the induction of regulatory CD4+ T cells and co-inhibitory interactions to maintain immune homeostasis after vaccination...
December 5, 2022: The innovation